
Jeanette E. Chapman
Examiner (ID: 16208, Phone: (571)272-6841 , Office: P/3638 )
| Most Active Art Unit | 3635 |
| Art Unit(s) | 3635, 2407, 3633, 3638, 3765, 3764, 3711, 3408, 3741, 3625, 2773 |
| Total Applications | 2706 |
| Issued Applications | 2056 |
| Pending Applications | 100 |
| Abandoned Applications | 562 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15931807
[patent_doc_number] => 20200157537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
[patent_app_type] => utility
[patent_app_number] => 16/664527
[patent_app_country] => US
[patent_app_date] => 2019-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16664527
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/664527 | Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1) | Oct 24, 2019 | Abandoned |
Array
(
[id] => 19076696
[patent_doc_number] => 11946047
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Treatment strategies against anthrax by interfering with critical host factors
[patent_app_type] => utility
[patent_app_number] => 16/660986
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 34
[patent_no_of_words] => 17333
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660986
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/660986 | Treatment strategies against anthrax by interfering with critical host factors | Oct 22, 2019 | Issued |
Array
(
[id] => 16177225
[patent_doc_number] => 20200224193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => METHOD OF MANUFACTURING VESICLES BY DELIVERY OF RNA NANOPARTICLES AND VESICLES MANUFACTURED USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/596553
[patent_app_country] => US
[patent_app_date] => 2019-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596553
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/596553 | METHOD OF MANUFACTURING VESICLES BY DELIVERY OF RNA NANOPARTICLES AND VESICLES MANUFACTURED USING THE SAME | Oct 7, 2019 | Abandoned |
Array
(
[id] => 15866931
[patent_doc_number] => 20200140869
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => MODULATORS OF PNPLA3 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/574407
[patent_app_country] => US
[patent_app_date] => 2019-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16574407
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/574407 | Modulators of PNPLA3 expression | Sep 17, 2019 | Issued |
Array
(
[id] => 19367369
[patent_doc_number] => 12059429
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-13
[patent_title] => Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells
[patent_app_type] => utility
[patent_app_number] => 16/572234
[patent_app_country] => US
[patent_app_date] => 2019-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 64
[patent_no_of_words] => 21574
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 224
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572234
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/572234 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | Sep 15, 2019 | Issued |
Array
(
[id] => 15590329
[patent_doc_number] => 20200071699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-05
[patent_title] => TREATMENT OF ALZHEIMERS DISEASE WITH MICRO RNA AND GHRELIN
[patent_app_type] => utility
[patent_app_number] => 16/559568
[patent_app_country] => US
[patent_app_date] => 2019-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16559568
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/559568 | TREATMENT OF ALZHEIMERS DISEASE WITH MICRO RNA AND GHRELIN | Sep 2, 2019 | Abandoned |
Array
(
[id] => 16206893
[patent_doc_number] => 20200239883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => Compositions for Modulating Expression of C9ORF72 Antisense Transcript
[patent_app_type] => utility
[patent_app_number] => 16/554115
[patent_app_country] => US
[patent_app_date] => 2019-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21789
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16554115
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/554115 | Compositions for modulating expression of C9ORF72 antisense transcript | Aug 27, 2019 | Issued |
Array
(
[id] => 15619401
[patent_doc_number] => 20200080105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => RNAI STRATEGIES FOR CONTROL OF WHITEFLY
[patent_app_type] => utility
[patent_app_number] => 16/551847
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11045
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16551847
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/551847 | RNAi strategies for control of whitefly | Aug 26, 2019 | Issued |
Array
(
[id] => 15210479
[patent_doc_number] => 20190367926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATION
[patent_app_type] => utility
[patent_app_number] => 16/540973
[patent_app_country] => US
[patent_app_date] => 2019-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16540973
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/540973 | Methods and compositions for treating malignant tumors associated with KRAS mutation | Aug 13, 2019 | Issued |
Array
(
[id] => 17112171
[patent_doc_number] => 20210292768
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITIS
[patent_app_type] => utility
[patent_app_number] => 17/266556
[patent_app_country] => US
[patent_app_date] => 2019-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21565
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266556
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266556 | COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITIS | Aug 7, 2019 | Abandoned |
Array
(
[id] => 16429444
[patent_doc_number] => 10829511
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-11-10
[patent_title] => Molecular recognition systems with pyrimidine analog pairing
[patent_app_type] => utility
[patent_app_number] => 16/530600
[patent_app_country] => US
[patent_app_date] => 2019-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 8155
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530600
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/530600 | Molecular recognition systems with pyrimidine analog pairing | Aug 1, 2019 | Issued |
Array
(
[id] => 16353360
[patent_doc_number] => 10793862
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Compositions and methods for modulating growth hormone receptor expression
[patent_app_type] => utility
[patent_app_number] => 16/521344
[patent_app_country] => US
[patent_app_date] => 2019-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 110843
[patent_no_of_claims] => 56
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521344
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/521344 | Compositions and methods for modulating growth hormone receptor expression | Jul 23, 2019 | Issued |
Array
(
[id] => 15931829
[patent_doc_number] => 20200157548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/449093
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 265
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16449093
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/449093 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | Jun 20, 2019 | Abandoned |
Array
(
[id] => 15436155
[patent_doc_number] => 20200032261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => METHODS AND COMPOSITIONS FOR CONTROLLING EFFICACY OF RNA SILENCING
[patent_app_type] => utility
[patent_app_number] => 16/440722
[patent_app_country] => US
[patent_app_date] => 2019-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28391
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16440722
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/440722 | Methods and compositions for controlling efficacy of RNA silencing | Jun 12, 2019 | Issued |
Array
(
[id] => 16941268
[patent_doc_number] => 11053497
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Antisense nucleic acids
[patent_app_type] => utility
[patent_app_number] => 16/437130
[patent_app_country] => US
[patent_app_date] => 2019-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 11620
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437130
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/437130 | Antisense nucleic acids | Jun 10, 2019 | Issued |
Array
(
[id] => 15432353
[patent_doc_number] => 20200030359
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => INHIBITION OF STRESS GRANULE FORMATION THROUGH MANIPULATION OF UBAP2L
[patent_app_type] => utility
[patent_app_number] => 16/431486
[patent_app_country] => US
[patent_app_date] => 2019-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16431486
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/431486 | Inhibition of stress granule formation through manipulation of UBAP2L | Jun 3, 2019 | Issued |
Array
(
[id] => 15436153
[patent_doc_number] => 20200032260
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF IKBKAP SPLICING
[patent_app_type] => utility
[patent_app_number] => 16/422128
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20417
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422128
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/422128 | Compositions and methods for modulation of IKBKAP splicing | May 23, 2019 | Issued |
Array
(
[id] => 16961563
[patent_doc_number] => 20210213062
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => Drug-Resistant Immune Cells and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/056233
[patent_app_country] => US
[patent_app_date] => 2019-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45451
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17056233
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/056233 | Drug-resistant immune cells and methods of use thereof | May 15, 2019 | Issued |
Array
(
[id] => 15114471
[patent_doc_number] => 20190343868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 16/409173
[patent_app_country] => US
[patent_app_date] => 2019-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25682
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409173
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/409173 | Benzimidazoles that enhance the activity of oligonucleotides | May 9, 2019 | Issued |
Array
(
[id] => 19151382
[patent_doc_number] => 11976281
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-07
[patent_title] => Therapeutic uses and methods
[patent_app_type] => utility
[patent_app_number] => 16/404561
[patent_app_country] => US
[patent_app_date] => 2019-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 9
[patent_no_of_words] => 20824
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16404561
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/404561 | Therapeutic uses and methods | May 5, 2019 | Issued |